Retrospective cohort study finds delayed IV-to-oral antibiotic switching links to higher failure and mortality in hospitalized adults, suggesting timing reflects unmeasured clinical severity.
Objective This retrospective cohort study aims to assess associations of delayed Intravenous (IV)-to-Oral switch after 72-hours versus early switch within 72-hours with switch failure within 7-days and with adjusted post switch clinical outcomes in hospitalized adults.Methods Adult admissions with an IV-antibiotic regimen followed by an oral regimen in the same hospitalization were included. Early-switch occurred within 72-hours of admission and delayed-switch occurred after 72-hours. Switch failure within 7-days was defined as IV restart/antibiotic escalation within 7-days after the switch. Adjusted models estimated associations with post switch length of stay (LOS), in-hospital mortality, ICU transfer and vasopressor initiation within 7-days.Results The cohort included 3898 admissions with 2002 delayed-switches and 1896 early switches. Switch failure within 7-days occurred in 14.7% after delayed switching and 6.4% after early-switching. Delayed-switching was associated with longer post switch LOS with adjusted ratio 1.94 (1.70-to-2.22) and higher odds of in-hospital mortality with aOR = 2.29 (1.21-to-4.34). Vasopressor initiation within 7-days was higher with delayed switching with aOR = 9.68 (2.28-to-41.04). ICU transfer within 7-days didn’t show a clear adjusted difference. Delayed-switching was also associated with higher odds of IV restart within 7-days with aOR = 2.24 (1.79-to-2.81).Conclusion Delayed switching after 72 hours was associated with more 7-day events and worse adjusted outcomes. However, switch timing is a clinician-, policy-, and resource-dependent surrogate for underlying clinical status rather than a direct measure of disease severity or a cause of deterioration. Clinical interpretation should therefore rely on direct measures of physiologic stability, infection severity, source control, microbiology, and oral-treatment feasibility.
No takes yet. Share an insight, caveat, or question.
Orayj et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: